EU Changes Mind on Nivo Plus Ipi for Kidney Cancer EU Changes Mind on Nivo Plus Ipi for Kidney Cancer
Positive opinions were given for the first-line use of the immunotherapy combination nivolumab and ipilimumab in kidney cancer and for an extension of indication for blinatumomab in certain leukemia patients.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Kidney Cancer | Leukemia | Urology & Nephrology | Yervoy